A refinement diff. v3 clarifies the terminology for genetic sequencing data to "genome sequence data" in Section 2(2)(C) and expands reporting requirements in Section 3(n)(1) to include revisions based on recent recalls. Additionally, Section 3(n)(4)(A) now explicitly mentions botulism and other contaminants in the context of contamination events, providing greater specificity.
Protect Infant Formula from Contamination Act
- Sponsor
- Sen. Peters, Gary C. [D-MI]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- May 4, 2026
Bottom line
This bill strengthens regulatory oversight and reporting requirements for infant formula manufacturers to prevent contamination and improve the stability of the infant formula supply chain.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to enhance infant formula safety by requiring manufacturers to notify the Food and Drug Administration (FDA) within one business day of confirmed microorganism contamination, consult on product isolation, and provide test data, including whole genome sequence data. It also mandates the FDA to respond quickly, confirm manufacturer investigations, and issue regular reports to Congress on infant formula safety and supply chain resiliency.
Proponents argue
Supporters argue that this bill is a critical public health measure, directly addressing vulnerabilities exposed by past infant formula recalls and shortages. They contend it will ensure quicker FDA intervention in contamination events, enhance transparency, and build a more resilient supply chain, thereby protecting vulnerable infants and reassuring parents.
Opponents contend
No significant organized opposition arguments have been publicly documented against the core intent of improving infant formula safety and supply. Potential industry concerns, if any, would likely focus on the operational challenges and costs associated with the stringent new reporting timelines and data requirements, rather than opposing the bill's fundamental goals.
The bill is short and clearly written, making it highly accessible for a thorough understanding in a short amount of time.
Section 2, amending 21 U.S.C. 350a(e)
Mandatory 1-Business Day Notification for Microorganism Contamination
This provision requires infant formula manufacturers to notify the Secretary of Health and Human Services (FDA) within one business day of confirming a positive test result for any microorganism for which finished product testing is required. This notification is mandatory regardless of whether the product has left the manufacturer's control. Manufacturers must also promptly consult with the Secretary for proper product isolation and provide test results, including whole genome sequence data, from positive samples.
Supporters argue
Supporters argue this provision is essential for public health, enabling rapid intervention by the FDA to prevent contaminated infant formula from reaching consumers. This swift action is critical to protect vulnerable infants from serious illness or death, directly addressing lessons learned from past contamination crises.
Critics contend
While direct opposition to infant safety is unlikely, manufacturers might express concerns about the strict 1-business-day timeline, arguing it could lead to premature notifications before full verification or impose significant operational challenges, especially for smaller manufacturers, potentially increasing compliance costs.
Tradeoffs
This provision balances the urgent need for a rapid public health response to contamination with the potential operational burdens on manufacturers and the risk of false alarms if the definition of 'confirmed positive' is not sufficiently robust.
Section 2, amending 21 U.S.C. 350a(e)
FDA Response and Manufacturer Investigation Confirmation
This provision mandates that the FDA respond to a manufacturer's contamination notification within one business day to initiate discussions regarding investigation and corrective action. Furthermore, within 90 days of receiving any notification, the FDA must confirm, through documentation and inspection, that the manufacturer performed an appropriate investigation and corrective action. The FDA's review must consider the analytical method used and the potential for cross-contamination.
Section 3, adding 21 U.S.C. 350a(n)(1)
FDA Progress Report on Infant Formula Strategy
This section directs the Secretary (FDA) to issue a progress report within 180 days of the bill's enactment. This report must detail the implementation of recommendations from the FDA's January 2025 'Long-Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market.' It must also include any additional authorities or resources the Secretary may require and any revisions to the recommendations resulting from subsequent infant formula recalls.
Section 3, adding 21 U.S.C. 350a(n)(2)
Quarterly Infant Formula Supply Chain Reports to Congress
This provision requires the Secretary (FDA) to submit quarterly reports for a five-year period, beginning 270 days after enactment, to specific Congressional committees. These reports must detail the most current critical supply chain data for infant formula, including in-stock rates, providing ongoing visibility into the market's stability.
Section 3, adding 21 U.S.C. 350a(n)(3) & (4)
Interagency Consultation and Triennial Adequacy of Supply Reports
This provision mandates the Secretary (FDA) to engage with the Department of Agriculture and other relevant federal agencies to address immediate formula needs and build long-term market resiliency. Additionally, at 1, 3, and 5 years after enactment, the Secretary must engage with public stakeholders and manufacturers to identify evidence-based practices for maximizing infant formula supply and safety (including high-frequency testing and corrective action impacts), and then submit reports to Congress detailing any recommended modifications to manufacturer practices.
Requires manufacturers to promptly provide the Secretary with results and isolates from a positive sample or the whole genome sequence data from any confirmed positive analytical result.
Section 2, amending 21 U.S.C. 350a(e)(2)(C)
Why it matters:This is standard legislative practice for specifying technical requirements within a broader regulatory framework. It is not intentionally hidden but is a detailed component of the overall amendment.
Case for: Proponents argue that requiring whole genome sequencing data provides critical information for the FDA to trace contamination sources, understand pathogen characteristics, and develop more effective prevention and control strategies, significantly enhancing public health protection and outbreak response capabilities.
Case against: Manufacturers might express concerns about the cost and technical capacity required to perform whole genome sequencing, especially for smaller companies. They might also raise questions about data privacy, intellectual property, and the secure transmission of such detailed biological information.
Estimated impact: Enhances the FDA's investigative capabilities for contamination events, potentially leading to faster and more precise root cause identification, targeted recalls, and improved public health outcomes.